HomepageDRREDDY • NSE
add
Dr Reddy's Laboratories Ltd
Vorige slotkoers
₹ 1.195,35
Dag-range
₹ 1.193,60 - ₹ 1.223,20
Jaar-range
₹ 1.074,00 - ₹ 1.421,49
Beurswaarde
1,01 bln. INR
Gem. volume
1,48 mln.
Koers/winst
18,96
Dividendrendement
0,66%
Primaire beurs
NSE
In het nieuws
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
(INR) | sep 2024info | Wijziging j-o-j |
---|---|---|
Opbrengst | 80,16 mld. | 16,51% |
Bedrijfskosten | 29,72 mld. | 24,54% |
Netto inkomsten | 12,55 mld. | -15,18% |
Netto winstmarge | 15,66 | -27,20% |
Winst per aandeel | 15,83 | -11,13% |
EBITDA | 22,02 mld. | 8,53% |
Effectief belastingtarief | 30,01% | — |
Balans
Totale activa
Totale passiva
(INR) | sep 2024info | Wijziging j-o-j |
---|---|---|
Contanten en kortetermijnbeleggingen | 63,07 mld. | -7,15% |
Totale activa | 465,96 mld. | 34,27% |
Totale passiva | 156,67 mld. | 66,79% |
Totaal aandelenvermogen | 309,28 mld. | — |
Uitstaande aandelen | 833,05 mln. | — |
Koers-boekwaardeverhouding | 3,26 | — |
Rendement op activa | 10,24% | — |
Rendement op kapitaal | 13,21% | — |
Kasstroom
Nettomutatie in liquide middelen
(INR) | sep 2024info | Wijziging j-o-j |
---|---|---|
Netto inkomsten | 12,55 mld. | -15,18% |
Operationele kasstroom | 9,32 mld. | -48,03% |
Kasstroom uit beleggingen | -19,07 mld. | -322,21% |
Kasstroom uit financiering | 16,15 mld. | 329,53% |
Nettomutatie in liquide middelen | 6,37 mld. | 1,03% |
Vrije kasstroom | 3,92 mld. | -72,47% |
Over
Dr. Reddy's Laboratories is an Indian multinational pharmaceutical company based in Hyderabad. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients for drug manufacture, diagnostic kits, critical care, and biotechnology.
Dr. Reddy's began as a supplier to Indian drug manufacturers, but it soon started exporting to other less-regulated markets that had the advantage of not having to spend time and money on a manufacturing plant that would gain approval from a drug licensing body such as the U.S. Food and Drug Administration. By the early 1990s, the expanded scale and profitability from these unregulated markets enabled the company to begin focusing on getting approval from drug regulators for their formulations and bulk drug manufacturing plants – in more-developed economies. This allowed their movement into regulated markets such as the US and Europe.
By 2007, Dr. Wikipedia
CEO
Opgericht
1984
Hoofdvestiging
Website
Werknemers
27.048